Robin K. Dore

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve‐month, multicenter, randomized, double‐blind, placebo‐controlled, phase II clinical trial

Stanley Cohen, Robin K. Dore, Nancy E. Lane et al. · Arthritis & Rheumatism · 2008 · 564 citations

A Randomized Double-Blind Trial to Compare the Efficacy of Teriparatide [Recombinant Human Parathyroid Hormone (1–34)] with Alendronate in Postmenopausal Women with Osteoporosis

Jean‐Jacques Body, Gregory Gaich, Wim H. Scheele et al. · The Journal of Clinical Endocrinology & Metabolism · 2002 · 359 citations

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis

Henry G. Bone, Felicia Cosman, Paul D. Miller et al. · The Journal of Clinical Endocrinology & Metabolism · 2018 · 195 citations · Full text

Cevimeline for the Treatment of Xerostomia in Patients With Sjögren Syndrome

Rose Fife, Walter F. Chase, Robin K. Dore et al. · Archives of Internal Medicine · 2002 · 194 citations · Full text

Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates

Robin K. Dore, Stanley Cohen, Nancy E. Lane et al. · Annals of the Rheumatic Diseases · 2009 · 192 citations · Full text